MedTrace Logo

Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer

NCT00003683 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-21

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and ifosfamide in treating patients who have metastatic kidney cancer.

Conditions

Interventions

DRUG

doxorubicin hydrochloride

DRUG

ifosfamide

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Stephane Culine, MD · Institut du Cancer de Montpellier - Val d'Aurelle

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-03-31
Primary Completion
2000-11-05
Completion
2002-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003683 on ClinicalTrials.gov